XALIA: First Published, Prospective, International, Observational Study with a NOAC (Xarelto®) in DVT 1
- Collect Real World data in patients with acute DVT treated with Xarelto or standard anticoagulation therapya,1
- A large, multicentre, prospective, non-interventional study to evaluate the safety and efficacy of Xarelto in the Real World1
- Patients were enrolled from June 2012 to March 2014 from 19 countries in Europe, plus Canada and Israel1
5,142 adults with acute DVT and an indication to receive anticoagulation therapy for at least 3 months, who were treated with Xarelto or standard anticoagulation therapya,1
Key patient characteristics of Xarelto patients are consistent with EINSTEIN DVT2
DVT, deep vein thrombosis . CrCl, creatinine clearance. VTE , venous thromboembolism. aInitial treatment with unfractionated heparin, low-molecular-weight heparin or fondaparinux; usually overlapping with and followed by a vitamin K antagonist.